ISDA

Entry Detail

PDB ID:

6XID

Keywords:

HYDROLASE/INHIBITOR

Title:

PCSK9(deltaCRD) in complex with cyclic peptide 51

Biological Source:

Source Organism:

Homo sapiens, synthetic construct

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2020-06-19

Release Date:

2020-11-18

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.48 Å

R-Value Free:

0.20

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Proprotein convertase subtilisin/kexin type 9
Chain IDs:A
Chain Length:122
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q8NBP7 Pfam ID:PF05922, PF00082 EC:3.4.21.61

Protein Blast

Polymer Type:polypeptide(L)
Description:Proprotein convertase subtilisin/kexin type 9
Chain IDs:B
Chain Length:308
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q8NBP7 Pfam ID:PF05922, PF00082 EC:3.4.21.61

Polymer Type:polypeptide(L)
Description:Peptide 51
Chain IDs:C (auth: I)
Chain Length:11
Number of Molecules:1
Biological Source:synthetic construct

Ligand Molecules

GOL

Primary Citation

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.

Alleyne, C, Amin, R.P, Bhatt, B, Bianchi, E, Blain, J.C, Boyer, N, Branca, D, Embrey, M.W, Ha, S.N, Jette, K, Johns, D.G, Kerekes, A.D, Koeplinger, K.A, LaPlaca, D, Li, N, Murphy, B, Orth, P, Ricardo, A, Salowe, S, Seyb, K, Shahripour, A, Stringer, J.R, Sun, Y, Tracy, R, Wu, C, Xiong, Y, Youm, H, Zokian, H.J, Tucker, T.J.Show

J.Med.Chem. 63 13796 13824 (2020)

PMID: 33170686 DOI: 10.1021/acs.jmedchem.0c01084

Abstact

Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein-protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures